Heart Failure With Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation clinical trials

Explore recruiting heart failure with mildly reduced or preserved ejection fraction and systemic inflammation clinical trials.

Recruiting heart failure with mildly reduced or preserved ejection fraction and systemic inflammation studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Heart Failure With Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

HERMES: Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation

Denmark, France, Ireland, Italy, Croatia, Slovenia +18 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

ATHENA: Effects of ziltivekimab versus placebo on heart failure symptoms and physical function in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation

Poland, Czechia, Germany, France, Greece, Bulgaria +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Heart Failure With Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation trials by city

Heart Failure With Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation in Toronto Heart Failure With Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation in Vancouver Heart Failure With Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation in Montreal Heart Failure With Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation in Calgary Heart Failure With Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation in Edmonton Heart Failure With Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation in Ottawa Heart Failure With Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation in Winnipeg Heart Failure With Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation in Quebec City Heart Failure With Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation in Hamilton Heart Failure With Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation in Kitchener Heart Failure With Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation in London Heart Failure With Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation in Halifax Heart Failure With Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation in New York Heart Failure With Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation in Los Angeles Heart Failure With Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation in Chicago Heart Failure With Mildly Reduced Or Preserved Ejection Fraction And Systemic Inflammation in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease